This study reported the efficacy and safety of image-guided proton therapy (IGPT) for elderly (≥80 years old) hepatocellular carcinoma (HCC) patients. Seventy...

Thirty patients with caudate lobe HCC were treated to a total doses of 55 to 77 (median 72.6) GyRBE. The median follow-up period was 37.5 months. The OS rates...

This study analyzed 46 patients with 49 liver metastases treated by PBT to a total dose of 60 GyRBE in 5 fractions (BED 132 GyE) or 70 GyRBE in 10 (BED 119 GyE)...

Based on twenty-six primary studies including 1,809 participants, this review reported that microwave ablation (MWA) (p < 0.001) and particle radiotherapy (p <...

A random-effects meta-analysis was conducted based on 9 original studies with a total 1558 patients (seven photon, n = 1488 patients; two PT, n = 70 patients)...

For unresectable oligometastases or nonsurgical candidates, SBRT has a growing role with recent randomized phase II trial data indicating a doubling overall...

Ninety-five patients treated with PBT were analyzed compared to 836 patients treated by RFA as controls. The 1-year, 3-year, and 5-year recurrence-free survival...

Although proton treatment plans often showed advantages over photon plans in reducing dose to OARs, the clinical implications were yet to be proven. The key...

Fifteen patients received proton therapy delivered 40.5 GyRBE in 18 fractions to the gross disease and elective nodal volumes followed by 22.5 GyRBE as a 10...

Based on 32 publications, this review reported that significant benefits with PBT suggested by current literature in terms of toxicity reduction, especially in...